

IAP5 Rec'd PCT/PTO 29 SEP 2006

New claims

- 5 1. The use of a conjugate comprising a carboxyl group-containing organic compound and albumin for producing a pharmaceutical for modulating a transplantation-associated immune response, the conjugate being obtainable by reacting the carboxyl group-containing organic compound and albumin in the presence of 1-ethyl-3-(3-dimethylamino-propyl)carbonyldiimide as activating reagent.
- 10
2. The use as claimed in claim 1 for producing a pharmaceutical for preventing a transplantation-associated immune response.
- 15
3. The use as claimed in claim 1 or 2 for producing a pharmaceutical for the prophylaxis or/and treatment of GVHD (graft versus host disease).
- 20
4. The use as claimed in claim 3, characterized in that GVHD is an acute GVHD.
5. The use as claimed in claim 3, characterized in that GVHD is a chronic GVHD.
- 25
6. The use as claimed in any of the preceding claims, characterized in that the transplantation is a bone marrow transplantation.
- 30
7. The use as claimed in any of claims 1 to 5, characterized in that the transplantation is an organ transplantation, in particular a kidney, heart or liver transplantation.
- 35

AMENDED SHEET

8. The use as claimed in any of the preceding claims, characterized in that the transplantation is an allogeneic transplantation.

5 9. The use as claimed in any of the preceding claims, characterized in that the carboxyl group-containing organic compound is selected from cytostatics or immunosuppressants.

10 10. The use as claimed in any of the preceding claims, characterized in that the carboxyl group-containing organic compound is methotrexate or aminopterin and/or N-phthaloyl-L-glutamic acid.

15 11. The use as claimed in any of the preceding claims, characterized in that the carboxyl group-containing compound:albumin molar ratio is from 10:1 to 1:10, in particular 1.5:1 to 1:1.5.

20 12. The use as claimed in any of the preceding claims, characterized in that the albumin is human albumin.

13. The use as claimed in any of the preceding claims, characterized in that the albumin is a native human
25 albumin.

14. The use as claimed in any of the preceding claims, characterized in that the conjugate is a methotrexate-albumin conjugate.

30 15. A method for preparing a conjugate comprising
i) a carboxyl group-containing organic compound and
ii) albumin,
characterized in that a carboxyl group-containing
35 organic compound and albumin are reacted in the
presence of 1-ethyl-3-(3-dimethylamino-
propyl)carbonyldiimide as activating reagent.

16. The method as claimed in claim 15, characterized in that the carboxyl group-containing organic compound is a cytostatic or an immunosuppressant.

5 17. The method as claimed in claim 15 or 16, characterized in that the carboxyl group-containing organic compound is methotrexate, aminopterin and/or N-phthaloyl-L-glutamic acid.

10 18. The method as claimed in claim 17, characterized in that the carboxyl group-containing organic compound is methotrexate.

15 19. The method as claimed in claim 18, characterized in that the carboxyl group-containing compound:albumin molar ratio is from 10:1 to 1:10, in particular 1.5:1 to 1:1.5.

20 20. The method as claimed in any of claims 15 to 19, characterized in that the carboxyl group-containing organic compound is reacted in an organic solvent, in particular in an anhydrous organic solvent, with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, is activated by heating and then the activated carboxyl
25 group-containing organic compound is reacted with the protein.